UBS Group’s BeOne Medicines ONC Stock Holding History
Bought
Maintained
Sold
Other funds holding ONC
BBA
UBS Group's ONC Position: Q3 2026 in Review
UBS Group reduced its BeOne Medicines (ONC) stake by 9.7% in Q3 2026, selling an estimated $8.54M and leaving 233,620 shares worth $85.5M. The position accounts for 0.01% of the portfolio, ranked #1220.
UBS Group first reported a position in ONC in Q1 2016 and has held it in 41 quarters since. The position peaked at $123M in Q1 2026. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.
- UBS Group held 233,620 shares of BeOne Medicines worth $85.5M as of Q3 2026.
- UBS Group sold 24,969 BeOne Medicines shares in Q3 2026, an estimated $8.54M.
- BeOne Medicines made up 0.01% of UBS Group's portfolio in Q3 2026, its #1220 holding.
- UBS Group first reported a position in BeOne Medicines in Q1 2016 and has held it in 41 quarters since.
- UBS Group's BeOne Medicines position peaked at $123M in Q1 2026.
- 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.